Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 227 participants.

Also called NCT06122779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 227 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06122779
  • EudraCT 2023-505919-21
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Canada, China, Israel, Italy, Japan, Poland, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06122779. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-07 (actual); primary completion 2026-12-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Acronym
AURORA-HFpEF
Condition
Heart Failure
Intervention (Drug)
BMS-986435
Intervention (Other)
Placebo
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct06122779
Content hash
76b7a972121f6df976e66708643f65882a2bec76db1376332bfccbb708b04c73